New Influenza Vaccine Demonstrates Enhanced Protection for Older Adults
A Phase 3 study published in The Lancet shows a new influenza vaccine is effective in older adults. The vaccine combines three approaches to enhance protection.
CSL Seqirus has announced positive results from a Phase 3 clinical trial for a new influenza vaccine aimed at older adults. The study, published in The Lancet, demonstrates that the vaccine offers enhanced protection compared to existing options for this demographic.
The vaccine utilizes a novel approach by combining three distinct strategies designed to strengthen the immune response against influenza. This is particularly important for older adults, who are at a higher risk of severe illness from the flu.
The trial involved thousands of participants aged 65 and over across multiple countries. Data indicated that the vaccine was effective in preventing symptomatic influenza and its associated complications. The company believes this multifaceted approach represents a significant advance in flu prevention for the elderly.
CSL Seqirus intends to seek regulatory approval for the vaccine. If approved, it could play a crucial role in public health efforts to reduce the burden of influenza in aging populations.